Radiation Therapy with or without Chemotherapy in Treating Patients with High-Risk Malignant Salivary Gland Tumors That Have Been Removed by Surgery
Inclusion Criteria
- Pathologically proven diagnosis of a malignant major salivary gland tumor or malignant minor salivary gland tumor of the head and neck of the following histologic subtypes: * Intermediate-grade adenocarcinoma or intermediate-grade mucoepidermoid carcinoma * High-grade adenocarcinoma or high-grade mucoepidermoid carcinoma or salivary duct carcinoma * High-grade acinic cell carcinoma or high-grade (> 30% solid component) adenoid cystic carcinoma * Patients with diagnoses such as "undifferentiated or poorly differentiated carcinoma", "carcinoma-ex pleomorphic adenoma", "carcinoma not otherwise specified (NOS)" and others should be considered for this trial
- Surgical resection with curative intent within 8 weeks prior to registration
- Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (=< 1 mm) or microscopically positive surgical margin (American Joint Committee on Cancer [AJCC], 7th edition); patients must be free of distant metastases based upon the following minimum diagnostic workup: * History/physical examination within 8 weeks prior to registration * Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration; at a minimum, contrast computed tomography (CT) imaging of the chest is required; positron emission tomography (PET)/CT is acceptable
- Zubrod performance status 0-1
- Absolute neutrophil count (ANC) >= 1,800 cells/mm^3 (within 8 weeks prior to registration)
- Platelets >= 100,000 cells/mm^3 (within 8 weeks prior to registration)
- Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable) (within 8 weeks prior to registration)
- Serum creatinine < 2.0 mg/dl (within 8 weeks prior to registration)
- Total bilirubin < 2 x the institutional upper limit of normal (ULN) (within 8 weeks prior to registration)
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN (within 8 weeks prior to registration)
- Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential
- Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment and for 6 weeks following treatment
- All patients must have a Medical Oncology evaluation within 4 weeks prior to registration
- Patients must be deemed able to comply with the treatment plan and follow-up schedule
- Patients must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for central review
Exclusion Criteria
- Patients with residual macroscopic disease after surgery
- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
- Prior systemic chemotherapy or radiation therapy for salivary gland malignancy; note that prior chemotherapy for a different cancer is allowable
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
- Severe, active co-morbidity, defined as follows: * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months * Transmural myocardial infarction within the last 6 months * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, coagulation parameters are not required for entry into this protocol * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol * Pre-existing >= grade 2 neuropathy * Prior organ transplant
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
- Significant pre-existing hearing loss, as defined by the patient or treating physician
Alabama
Birmingham
Arizona
Gilbert
Peoria
Phoenix
Scottsdale
Surprise
Tucson
California
Auburn
Bakersfield
Burlingame
Cameron Park
Carmichael
Duarte
La Jolla
Los Angeles
Marysville
Modesto
Newport Beach
Orange
Palo Alto
Roseville
Sacramento
San Francisco
Vacaville
Colorado
Aurora
Boulder
Colorado Springs
Denver
Englewood
Littleton
Longmont
Loveland
Thornton
Connecticut
Norwich
Delaware
Newark
Rehoboth Beach
Florida
Coral Gables
Deerfield Beach
Gainesville
Jacksonville
Miami
Orlando
Tampa
Georgia
Atlanta
Savannah
Idaho
Boise
Post Falls
Illinois
Chicago
Maywood
Springfield
Indiana
Carmel
Goshen
Indianapolis
South Bend
Iowa
Ames
Des Moines
Iowa City
Sioux City
Kansas
Kansas City
Kentucky
Lexington
Louisville
Louisiana
Baton Rouge
New Orleans
Maryland
Baltimore
Massachusetts
Boston
Michigan
Adrian
Ann Arbor
Brownstown
Clinton Township
Detroit
Farmington Hills
Flint
Kalamazoo
Livonia
Pontiac
Port Huron
Saginaw
Warren
West Bloomfield
Minnesota
Rochester
Mississippi
Jackson
Missouri
Columbia
Creve Coeur
Joplin
Rolla
Saint Louis
Saint Peters
Springfield
Montana
Billings
Bozeman
Kalispell
Nebraska
Omaha
Nevada
Henderson
Las Vegas
New Hampshire
Lebanon
New Jersey
Basking Ridge
Middletown
Montvale
Mount Holly
Newark
Sparta
Voorhees
New Mexico
Albuquerque
New York
Bay Shore
Brooklyn
Commack
Lake Success
New Hyde Park
New York
Rochester
Sleepy Hollow
Syracuse
Uniondale
West Harrison
North Carolina
Chapel Hill
Durham
Ohio
Akron
Barberton
Cincinnati
Cleveland
Columbus
Elyria
Medina
Mentor
Middleburg Heights
Parma
Salem
Sandusky
Sylvania
Toledo
West Chester
Wooster
Oklahoma
Oklahoma City
Oregon
Clackamas
Portland
Pennsylvania
Allentown
Bryn Mawr
Danville
Greensburg
Harrisburg
Hershey
Lewisburg
Lewistown
Moon Township
New Castle
Paoli
Philadelphia
Pittsburgh
Wilkes-Barre
Wynnewood
South Carolina
Boiling Springs
Charleston
Greenville
Greer
Seneca
South Dakota
Rapid City
Tennessee
Knoxville
Nashville
Texas
Conroe
Dallas
Houston
League City
Sugar Land
Utah
American Fork
Cedar City
Logan
Murray
Provo
Saint George
Salt Lake City
Vermont
Saint Johnsbury
Virginia
Fairfax
Falls Church
Hampton
Norfolk
Virginia Beach
Washington
Federal Way
Seattle
Vancouver
West Virginia
Morgantown
Wheeling
Wisconsin
Burlington
Fond Du Lac
Germantown
Grafton
Green Bay
Kenosha
Madison
Marinette
Milwaukee
Oshkosh
Racine
Sheboygan
Sturgeon Bay
Summit
Two Rivers
Wauwatosa
West Allis
Wisconsin Rapids
Alberta
Edmonton
Ontario
London
Sudbury
Toronto
Quebec
Montreal
Saudi Arabia
Riyadh
PRIMARY OBJECTIVES:
I. Determine the feasibility of conducting a cooperative group prospective clinical trial in patients with resected malignant salivary gland tumors. (Phase II)
II. Acquire preliminary efficacy data comparing postoperative radiotherapy alone to concurrent chemotherapy and radiation using weekly cisplatin. (Phase II)
III. Compare overall survival rates among patients receiving cisplatin and radiation to those receiving radiation alone. (Phase III)
SECONDARY OBJECTIVES:
I. Compare the acute toxicities of these 2 adjuvant treatments.
II. Compare late treatment-related adverse events in patients receiving postoperative radiation to those receiving concurrent chemoradiation.
III. Compare progression-free survival rates among patients receiving cisplatin and radiation to those receiving radiation alone in both the cohort of patients with pathologically high-risk disease (high-grade adenocarcinoma, high-grade mucoepidermoid carcinoma, salivary duct carcinoma), and the patient cohort with pathologically intermediate-risk disease (all other eligible diagnoses).
IV. Investigate quality of life and patient-reported outcomes in patients enrolled in the study.
V. Identify the histopathology and tumor marker expression from patients enrolled on this trial and assemble a tissue bank for future correlative studies.
VI. Establish an NRG Oncology baseline database for salivary gland malignancies to serve as a resource for future exploration of innovative and/or targeted approaches for this disease.
OUTLINE: Patients are stratified according to histology (intermediate-grade adenocarcinoma or intermediate-grade mucoepidermoid carcinoma vs high-grade adenocarcinoma, high-grade mucoepidermoid carcinoma or salivary duct carcinoma vs high-grade acinic cell carcinoma or high-grade [> 30% solid component] adenoid cystic carcinoma), nodal status (N0 vs N1-3), and type of radiation (photon vs proton). Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients undergo 3-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiation therapy (IMRT), or intensity modulated proton therapy (IMPT) 5 days a week for 6 or 6.5 weeks. Patients also receive cisplatin intravenously (IV) over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiotherapy.
Arm II: Patients undergo 3D-CRT, IMRT, or IMPT as in Arm I.
After completion of study treatment, patients are followed up at 3, 6, 9, 12, 18, and 24 months, every 6 months for 2 years, and then annually thereafter.
Trial Phase Phase II/III
Trial Type Treatment
Lead Organization
NRG Oncology
Principal Investigator
Cristina Paguia Rodriguez
- Primary ID RTOG-1008
- Secondary IDs NCI-2013-00370, NCI-2011-00795, CDR0000686072
- Clinicaltrials.gov ID NCT01220583